Harrow (HROW) Change in Accured Expenses (2010 - 2026)
Harrow's (HROW) quarterly Change in Accured Expenses came in at $3.4 million in Q1 2026, up 278.58% year-on-year from $892011.0 in Q1 2025, and down 87.93% quarter-over-quarter from $28.0 million in Q4 2025.
Harrow (HROW) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Harrow's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 278.58% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 86.07% decrease from a year earlier, with the FY2025 full-year figure at $936000.0, down 97.5% from the prior year.
- Change in Accured Expenses declined to $3.4 million in Q1 2026 per HROW's latest filing, from $28.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $35.8 million in Q4 2024 and bottomed at -$22.1 million in Q2 2025.
- The 5-year median for Change in Accured Expenses is -$598000.0 (2022), against an average of $2.6 million.
- Biggest YoY gain for Change in Accured Expenses was 27200.0% in 2024; the steepest drop was 704.59% in 2024.
- Year by year, Change in Accured Expenses stood at -$598000.0 in 2022, then surged by 121.91% to $131000.0 in 2023, then jumped by 27200.0% to $35.8 million in 2024, then dropped by 21.75% to $28.0 million in 2025, then slumped by 87.93% to $3.4 million in 2026.
- Per Business Quant, the three latest HROW Change in Accured Expenses figures stand at $3.4 million (Q1 2026), $28.0 million (Q4 2025), and -$3.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.70 Bn | 30.76 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.73 Bn | 23.67 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.18 Bn | 18.37 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.40 Bn | 1.31 Bn | 27.05 Mn | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.38 Mn |
| Mar 31, 2026 | 3.38 Mn |
| Dec 31, 2025 | 27.99 Mn |
| Dec 31, 2025 | 27.99 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -22.12 Mn |
| Jun 30, 2025 | -22.12 Mn |
| Mar 31, 2025 | -1.89 Mn |
| Mar 31, 2025 | -1.89 Mn |
| Dec 31, 2024 | 35.76 Mn |
| Dec 31, 2024 | 35.76 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Mar 31, 2024 | -8.94 Mn |
| Mar 31, 2024 | -8.94 Mn |
| Dec 31, 2023 | 131,000.00 |
| Dec 31, 2023 | 131,000.00 |